Will New Reforms Fix the ‘Fundamentally Broken’ PBM System?

Why It Matters

By decoupling PBM compensation from drug list prices, the reforms aim to lower prescription‑drug costs and increase pricing transparency for employers, patients, and providers. The measures also set a regulatory precedent that could reshape the broader pharmaceutical supply chain.

Key Takeaways

• Medicare Part D PBMs will receive flat fees, not percentage of list price.
• All manufacturer rebates must be passed fully to plan sponsors.
• New disclosure rules require semi‑annual reporting of spread pricing and formulary rationales.
• Reforms target Medicare, leaving Medicaid and commercial plans largely unchanged.
• Tennessee law forces PBM‑pharmacy divestiture, setting precedent for other states.

Pulse Analysis

The pharmacy‑benefit manager industry has become a focal point of criticism after a 2025 FTC report exposed massive mark‑ups on specialty generics, with the three largest PBMs—Optum Rx, Caremark Rx, and Express Scripts—handling roughly 80% of U.S. prescription claims. Their business model, built on spread pricing, administrative fees, and opaque rebate arrangements, has driven drug costs upward while offering little visibility to employers and patients. This concentration of power, coupled with historical safe‑harbor provisions, has prompted lawmakers to scrutinize the sector’s impact on overall health‑care spending.

The 2026 spending package tackles the issue by shifting Medicare Part D PBM compensation from a percentage of list price to a flat‑fee structure, effectively removing the incentive to favor higher‑priced drugs. Additionally, the law mandates that 100% of manufacturer rebates flow to plan sponsors and requires PBMs to disclose spread‑pricing details, formulary rationales, and rebate records on a semi‑annual basis. While these provisions promise greater transparency, they apply primarily to Medicare, leaving Medicaid and many commercial plans without comparable safeguards. Critics argue that without extending the rules, the reforms may only produce modest premium reductions.

State‑level initiatives are already complementing federal action. Tennessee’s recent PBM reform law forces divestiture of PBM‑owned pharmacies and requires rebate pass‑throughs to patients, while Missouri’s lawsuit targets insulin pricing practices. These efforts signal a growing consensus that the PBM model needs comprehensive overhaul, including stricter fiduciary duties and broader coverage of Medicaid. Physicians, as frontline advocates, can influence future policy by highlighting the clinical and financial burdens of opaque formulary decisions. Continued pressure from professional societies and lawmakers could eventually drive a more competitive, patient‑centric prescription‑drug market.